• Compare Products

  • Table of Contents

Custom VHH Antibody & Nanobody Discovery Service

Deliver single-domain antibodies with picomolar affinity and turnkey developability—ready in as little as six weeks. Our platform is optimized for therapeutic developability and ease of antibody engineering.

Why Choose Nanobodies?

  • 15 kDa—one-tenth the size of IgG for deep tissue or intracellular targets.
  • High solubility and stability in harsh pH or temperature shifts.
  • Straightforward engineering into bispecifics, CARs, imaging probes, or Fc-fusion half-life extensions.

Begin Inquiry

Get Your Quote

What Is Our Nanobody Discovery Service?

Built for programs that need better access to difficult targets, faster discovery timelines, and VHH candidates ready for engineering.

Difficult Targets
For targets with hard-to-reach epitopes or challenging binding sites.
Faster Discovery
For programs that need faster progress without long discovery delays.
Built for Engineering
For projects that need engineerable VHH candidates for downstream formats.
Alpaca

Our custom nanobody discovery service delivers an end-to-end VHH workflow—from immunization and screening to sequence recovery, expression, and validation.

Why Choose Boster for Custom Nanobody Discovery

In-House Camelid Farm in Wuhan

Our in-house llama herd in Wuhan supports a high-diversity VHH repertoire and a more consistent discovery supply chain.

Fast Turnaround

Optimized workflows and parallel processing help deliver custom nanobody candidates within 6 weeks.

Advanced Screening

Phage display, NGS, and BLI/SPR support precise affinity and specificity profiling.

Modular Engineering

Supports multimerization, Fc-fusion, PEGylation, and other tailored nanobody formats.

Regulatory & IND Support

GLP/GMP-ready workflows and IND-enabling support help smooth the path toward development.

Expert Team

Ph.D. scientists guide your project across screening, validation, and optimization.

Step-by-Step Discovery Workflow

Our streamlined 5-step pipeline delivers high-affinity nanobodies quickly and reliably:

  • Immunization & Bleed

    We immunize llamas at our Wuhan farm using your antigen of choice, then collect blood once peak VHH titers are reached.

  • Library Construction

    VHH-encoding genes are amplified from lymphocytes and cloned into a high-diversity phage-display library (>109 unique clones).

  • Phage Display Panning

    Successive rounds of panning against your target enrich for the strongest binders while depleting non-specific clones.

  • High-Throughput Screening (NGS, BLI)

    Next-generation sequencing tracks clone enrichment; biolayer interferometry measures binding kinetics to select top candidates.

  • Expression, Purification & Validation

    Lead VHHs are expressed recombinantly in E. coli, affinity-purified, and confirmed for specificity and affinity in orthogonal assays.

Decision Guide: Is a Nanobody Right for You?

Every research or therapeutic program has distinct requirements—and the right antibody format can make all the difference. Use this simple checklist to map your project needs against the strengths of each platform. Whether you need an ultra-compact binder, extended serum half-life, or lightning-fast screening, our guide will steer you toward the optimal solution. New to nanobodies? Read our introduction to how they work and where they fit best.

Project Need Recommended Format
Need a small, highly penetrant scaffold? Nanobody
Require long serum half-life? Fc-fusion or PEGylation
Looking for rapid screening? Phage-display sdAb

Use our guide to pick the optimum antibody format for your application.

Technology Comparison: Nanobody vs. Rabbit Monoclonal

Feature Nanobody (Library Display) Rabbit Monoclonal (High Throughput B cell isolation)
Throughput Very high (>10⁹ clones per library; phage library size ~10¹¹) Moderate (~10⁸ B cells harvested per bleed)
Epitope Range Linear & cryptic; accesses hidden or recessed epitopes Broad; favors conformational epitopes
Engineering Flexibility Exceptional (easy fusion, multimerization, humanization) Moderate (standard IgG formats; Fc engineering possible)
Cost Low–Moderate Low–Moderate
Timeline (post-immunization) ~6 weeks 8–12 weeks
When to Choose Small, highly soluble binders for imaging probes, bispecific formats, or rapid modular engineering. Full-length IgG with natural effector functions for diagnostics and assays.

Display-Platform Technical Comparison

Display Platform Library Size Sequence Diversity Timeline (post-immunization) PTM vs Human ER QC Golgi QC Membrane QC Developability
Phage Display 10¹¹ Low (scFv/Fab) Short Different ✗ ✗ ✗ Low
E. coli Display 10¹¹ Low (scFv/Fab) Short Different ✗ ✗ ✗ Low
Yeast Display 10¹⁰ Low (scFv/Fab) Medium Different ✓ ✓ ✗ Medium
Mammalian-Cell Display 10⁷ High (full-spectrum) Longer Identical ✓ ✓ ✓ High